BioMed Central launches Borderline Personality Disorder and Emotion Dysregulation

Open access publisher BioMed Central and the National Education Alliance for Borderline Personality Disorder (NEABPD) are pleased to announce the launch of Borderline Personality Disorder and Emotion Dysregulation. The journal is also an official publication of the Dachverband Dialektisch Behaviorale Therapie, an organization that supports research in the field of Borderline Personality Disorder and the development and training of evidence based-treatments, especially Dialectical Behaviour Therapy. 

Borderline Personality Disorder and Emotion Dysregulation will provide a venue for researchers and clinicians interested in borderline personality disorder (BPD) and in other conditions prominently characterized by emotion dysregulation, to share information and new knowledge about these conditions. The journal will publish research on the psychological, social and neurobiological aspects of emotion dysregulation, across, but not exclusively from fields of epidemiology, phenomenology, pathophysiology, psychological and pharmacological treatment, neurobiology, genetics, and animal models. It will also welcome psychiatric or psychological research linked to BPD or emotion dysregulation.

The journal will be led by Editors–in-Chief Martin Bohus and Christian Schmahl from the Central Institute of Mental Health at Heidelberg University, and John M Oldham from The Menninger Clinic and Baylor College of Medicine.

Among the launch articles is a review evaluating current evidence for the co-occurrence and common and distinct psychopathologic symptoms of borderline personality disorder and attention deficit hyperactivity disorder, providing recommendations for future research needed to broaden our knowledge of these co-morbid conditions and advance the development of available treatment options. Borderline Personality Disorder and Emotion Dysregulation also launches with a study by Morey, presenting evidence that a key feature of BPD involves distinct perceptual distortions of various aspects of self in relationship to others.

Todd Hummel, Editorial Director, Clinical Medicine at BioMed Central says: “We’re delighted to announce the launch of Borderline Personality Disorder and Emotion Dysregulation with BioMed Central. With its unique scope, this journal is an exciting addition to our portfolio of psychiatry journals, and we’re looking forward to continued collaboration between the journal and its affiliated society, the National Education Alliance for Borderline Personality Disorder.”

Perry D. Hoffman, President NEABPD says: “The National Education Alliance is honored to have Borderline Personality Disorder and Emotion Dysregulation as its official journal. The publication is under the editorship of key leaders in the field and it is a privilege for us to participate with them on this important effort.

BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. @BioMedCentral

Springer Science+Business Media is a leading global scientific, technical and medical publisher, providing researchers in academia, scientific institutions and corporate R&D departments with quality content via innovative information products and services.

Springer Science+Business Media is the largest publisher of open access research; BioMed Central publishes over 260 journals and SpringerOpen 175.